Repligen CEO's Stock Sale Spooks Investors

Repligens CEO, Olivier Loeillot, sold 3,832 shares, following a pre-planned Rule 10b5-1 trading plan. Despite the sale, Loeillot still owns 54,246 shares. The stock dropped 5.3% due to the news, but investors see it as a temporary signal, not a game-changer for the companys core business. The stock is down 24.3% YTD, trading at $124.46, and a $1,000 investment from five years ago would now be worth $575.29. With biotech volatility cooling, this dip might attract bargain hunters looking at Repligens long-term growth in drug production tech. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/46a816a36bac0d6f